FDA warns website over unlawful sale of weight-loss drugs

The FDA said on Tuesday it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk's weight-loss drugs.

The FDA said on Tuesday it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk's weight-loss drugs. (Andrew Kelly, Reuters)


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON — The U.S. Food and Drug Administration said on Tuesday it had warned a website called ozempen.com against unlawfully selling versions of Novo Nordisk's weight-loss drugs.

Surging demand has outpaced supply for Novo's Ozempic, Eli Lilly's Mounjaro and other GLP-1 drugs that promote weight loss, fueling a growing global market for counterfeit versions.

The FDA said the website was offering unapproved versions of obesity and diabetes drugs Ozempic and Wegovy.

"These products are only available pursuant to a prescription from a licensed practitioner," the health regulator said.

Last month, the World Health Organization issued warnings on fake drugs claiming to contain the active ingredient found in Ozempic and Wegovy.

Lilly and Novo have sued several entities to stop them from selling products claiming to contain the active ingredients tirzepatide and semaglutide that are used in their respective popular diabetes and weight-loss drugs.

Related stories

Most recent Health stories

Related topics

U.S.Health
Christy Santhosh
    KSL.com Beyond Business
    KSL.com Beyond Series

    KSL Weather Forecast

    KSL Weather Forecast
    Play button